# A Study for Participants With Recurrent or Metastatic Squamous Cell Head and Neck Cancer

> **NCT01087970** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 69 (actual)

## Conditions studied

- Head and Neck Neoplasms

## Interventions

- **DRUG:** Pemetrexed
- **DRUG:** Cetuximab
- **DRUG:** Carboplatin
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT01087970
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08
- **Primary completion:** 2013-08
- **Final completion:** 2013-08
- **Target enrollment:** 69 (ACTUAL)
- **Last updated:** 2014-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01087970

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01087970, "A Study for Participants With Recurrent or Metastatic Squamous Cell Head and Neck Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01087970. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*